hsBCL9CT-24 Ac-LQTLR-[X]-IQR-[X]-L-[2-Nal]-amide stapled

Description

Blocks the Wnt pathway and inhibits the expression of TGFb1 in CT26 colon carcinoma cells, leading to the reduction of CCL20 and CCL22, two TGF-b– dependent chemokines critical for Treg cell recruitment into the tumour microenvironment.  hsBCL9CT-24 shows robust antitumour efficacy across multiple in vivo models.

See full description

Catalogue number crb1001394
Sequence (one letter code) Ac-LQTLR-[X]-IQR-[X]-L-[2-Nal]-amide stapled
Sequence (three letter code) Ac-Leu-Gln-Thr-Leu-Arg-[X]-Ile-Gln-Arg-[X]-Leu-[2-Nal]-NH2 stapled, Where X indicates (S)-2-(4'-pentenyl) Ala
Purity >95%
Storage -20°C
Molecular Weight 1628.0
References

Feng et al (2019) Pharmacological inhibition of b-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells.  Sci. Adv. 2019 5 eaau5240

Blocks the Wnt pathway and inhibits the expression of TGFb1 in CT26 colon carcinoma cells, leading to the reduction of CCL20 and CCL22, two TGF-b– dependent chemokines critical for Treg cell recruitment into the tumour microenvironment.  hsBCL9CT-24 shows robust antitumour efficacy across multiple in vivo models.

hsBCL9CT-24

Cat No. Pack Size Price Qty

crb1001394h

0.5mg

$112.50

crb1001394j

1mg

$150.00